Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with
a poor prognosis and no known cure. Survival time is often short because of limited …

Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Background Limited evidence exists to show that adding a third agent to platinum-doublet
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase
(ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the …

Importance Patterns-of-failure studies suggest that in metastatic non–small-cell lung cancer
(NSCLC) sites of gross disease at presentation are the first to progress when treated with …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …

Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer …